Effectiveness of Erlotinib Treatment in K-Ras Wild Type Lung Adenocarcinomas –Results of a Hungarian Observational Cohort Study (Motivate)
2012; Elsevier BV; Volume: 23; Linguagem: Inglês
10.1016/s0923-7534(20)33906-5
ISSN1569-8041
AutoresGyula Ostoros, Veronika Sárosi, György Losonczy, János Strausz, Edina Tolnay, László Molnár,
Tópico(s)Peptidase Inhibition and Analysis
Resumohistology, stage of disease, presence of BM, survial were collected and analyzed.A multivariate logistic regression model was used to identiy the predictors of BM.Results: Among 596 NSCLC patients with a mean follow-up time of 12.5± 12.5 months and a mortality rate of 62% at the last follow up, 187 (31%) experienced BM during their disease course.The accumulative incidence of BM was higher in patients with adenocarcinoma (ADC) than those with squamous cell carcinoma (SCC) (36% vs 13%, p < 0.001).On multivatiate analysis, female, age < 60 years, ADC and stage 3b/4 were significantly associated with BM (OR = 1.67, 95% CI = 1.06-2.63,p = 0.025, and OR = 1.89, 95% CI = 1.28-2.78,p = 0.001, and OR = 2.67, 95% CI = 1.35-5.26,p = 0.017, and OR = 3.94, 95% CI = 2.15-7.13,p < 0.001, respectively).The incidence of BM in stage 3b/4 NSCLC patients was 36% and varied from 14% to 59% in patients with or without identified risk facotrs.Specifically, ADC patients with age less than 60 years were more likely to experience BM than the elder with SCC (OR = 5.46, 95% CI = 2.79-10.71,p < 0.001).Additionally, prolonged survial after diagnosis of lung cancer heightened the risk of BM; its incidence was 42%, 54% and 64% in patients who survived longer than 3, 12 and 24 moths, respectively.Conclusion: We find that gender, age and histological subtype are independent factors predicting BM in NSCLC patients and suggest identification of patients at high risks for BM might help detect BM earlier and facilitate the design of clinical trials aming at the prevention of BM.
Referência(s)